ISSN No. 2073-5944                   Vol.18 No.2 August 2010
The roles of apo E genotype, gender and adipokines in blood plasma lipids in Caucasians with well-controlled type 2 diabetes
  1. Feher M. Diabetes: preventing coronary heart disease in a high risk group. Heart 2004;90(Suppl IV): 18-21.
  2. Grundy S. Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006;47:1093-1100.
  3. Krauss R. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004; 27:1496-1504.
  4. Erkelens DW. Insulin resistance syndrome and type 2 diabetes. Am J Cardiol 2001;88 (Suppl):38J-42J.
  5. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004; 89:2601-2607.
  6. Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 2005; 31:429-439.
  7. Hawkins M, Tonelli J, Kishore P, Stein D, Ragucci E, Gitig A Reddy K. Contribution of elevated free fatty acids to the lack of glucose effectiveness in type 2 diabetes. Diabetes 2003; 52:2748-2758.
  8. Rosin BL. The progression of cardiovascular risk to cardiovascular disease. Rev Cardiovasc Med 2007; 4:S3-8.
  9. Gil-Campos M, Canete R, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004;23:963-974.
  10. Rattarasarn C. Physiological and pathophysiological regulation of regional adipose tissue in the development of insulin resistance and type 2 diabetes. Acta Physiol 2006;186:87-101.
  11. Tamer L, Ercan B, Unlu A, Sucu N, Pekdemir H, Eskandari G, Atik U. The relationship between leptin and lipids in atherosclerosis. Indian Heart J 2002;54:692-696.
  12. Obineche E, Gillett M, Abdulle A, Sulaiman M, Al-Rokhaimi M. Leptin, lipids and lipid metabolism- related hormones in chronic renal failure in Arabia. Nephrology 2002; 7:115-120.
  13. Jaleel F, Jaleel A, Aftab J, Rahman MA. Relationship between adiponectin, glycemic control and blood lipids in diabetic type 2 postmenopausal women with and without complication of ischemic heart disease. Clin Chim Acta 2006;370:76-81.
  14. Ogawa T, Hirose H, Yamamoto Y, Nishikai K, Miyashita K, Nakamura H, Saito I, Saruta T. Relationships between soluble leptin receptor level and serum leptin and adiponectin levels, insulin resistance index, lipid profile and leptin receptor gene polymorphisms in Japanese population. Metabolism 2004; 53:879-885.
  15. Goodzari M, Babaahmadi-Rezaei H, Kadkhodaei-Eliaderani M, Haddadinezhad S. Relationship of serum adiponectin with blood lipids, HbA1c and hs-CRP in type II diabetic post-menopausal women. J Clin Lab Anal 2007;21:197-200.
  16. Ong K, Frysktyk J, Flyvbjerg A, Petry C, the Avon Longitudinal Study of Parents and Children Team, Ness A, Dunger D. Sex-discordant associations with adiponectin levels and lipid profiles in children. Diabetes 2006; 55:1337-1341.
  17. Jaleel F, Jaleel A, Aftab J, Rahman M. Leptin and blood lipid levels in post-menopausal diabetic women with and without complication of ischemic heart disease. Med Sci Monit 2006;12:CR382-386.
  18. Schneider JG, von Eynatten M, Scheikofer S, Naworth PP, Dugi K. Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care 2005; 28:2181-2186.
  19. Wu DM, Shen MH, Chu NF. Relationship between plasma leptin levels and lipid profiles among school children in Taiwan - the Taipei Children Heart Study. Eur J Epidemiol 2001;17:911-916.
  20. Ozata M, Gungor D, Turan M, Ozisik G, Bingol N, Ozgurtas T, Ozdemir IC. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects. J Clin Endocrinol Metab 2001; 86:3659-3664.
  21. Schwedler S, Filep J, Galle J, Wanner C, Potempa L. C-reactive protein: A family of proteins to regulate cardiovascular function. Am J Kidney Dis 2006; 47:212-222.
  22. Kobayashi S, Inoue N, Ohashi Y, Terashima M, Matsui K, Mori T, Fujita H, Awano K, Kobayashi K, Azumi H, Ejiri J, Hirata K, Kawashima S, Hayashi Y, Yokozaki H, Itoh H, Yokoyama M. Interaction of oxidative stress and inflammatory response in coronary plaque instability. Arterioscler Thromb Vasc Biol 2003;23:1398-1404.
  23. Murase T, Okubo M, Amemiya-Kudo M, Ebara T, Mori Y. Impact of elevated serum lipoprotein (a) concentrations on the risk of coronary heart disease in patients with type 2 diabetes mellitus. Metabolism 2008; 57:791-795.
  24. Milioti N, Bermudez-Fajardo A, Penichet ML, Oviedo-Orta E. Antigen-induced immunomodulation in the pathogenesis of atherosclerosis. Clin Dev Immun 2008; 723539.
  25. Oh JY, Barrett-Connor E; Rancho Bernardo Study Group. Apolipoprotein E polymorphism and lipid levels differ by gender and family history of diabetes: the Rancho Bernardo Study. Clin Genet 2001;60:132-137.
  26. Reznik Y, Pousse P, Herrou M, Morello R, Mahoudeau J, Drosdowsky MA, Fradin S. Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin-dependent diabetic patients: influence of apolipoprotein E polymorphism. Metabolism 1996; 45:63-71.
  27. Hirano T, Ito Y, Saegusa H, Yoshino G. A novel and simple method for quantification of small, dense LDL. J Lipid Res 2003;44:2193-2201.
  28. Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991;19 :5444.
  29. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
  30. Nam BH, Kannel WB, D'Agostino RB. Search for an Optimal Atherogenic Lipid Risk Profile: From the Framingham Study. Am J Cardiol 2006;97:372-375.
  31. Shoji T, Hatsuda S, Tsuchikura S, Shinohara K, Kimoto E, Koyama H, Emoto M, Nishizawa Y. Small low-density lipoprotein cholesterol concentration and carotid atherosclerosis. Atherosclerosis 2009; 202:582-588.
  32. Wilding J. The importance of free fatty acids in the development of type 2 diabetes. Diabet Med 2007;24:934-945.
  33. Barre D. The molecular nature and consequences of lipoprotein (a)’s association with platelets. Protein Pept Lett 2007;14:839-842.
  34. Tatti P, Maselli L, Buoanno A, DiMauro P, Strollo F. Leptin levels in diabetic and non diabetic subjects. Endocrine 2001;15:305-308.
  35. Wauters M, Considine R, Löfgren A, Van Broeckhoven C, Van der Auwera JC, De Leeuw I, Van Gaal L. Associations of leptin with body fat distribution and metabolic parameters in non-insulin dependent diabetic patients: no effect of apolipoprotein E polymorphism. Metabolism 2000; 49:724-730.
  36. Asakawa H, Tokunaga K, Kawakami F.Relationship of leptin level with metabolic disorders and hypertension in Japanese type 2 diabetes mellitus patients. J Diabetes Complications 2001;15:57-62.
  37. Buyukbese MA, Cetinkaya A, Kocabas R, Guven A, Tarakcioglu M. Leptin levels in obese women with and without type 2 diabetes mellitus. Mediators of Inflammation 2004; 13:321-325.
  38. Authors in article. Canadian Diabetes Association. 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Canadian J. Diabetes 2008;32 (Suppl. 1):iv-S201.
  39. Harris S, Worrall G, MacAulay A, Norton P, Webster-Bogaert S, Donner A, Murray A, Stewart M. Diabetes Management in Canada: Baseline results of the group practice diabetes management study. Canadian J Diabetes 2006; 30:131-137.
  40. Barre D, Griscti O, Mizier-Barre K, Hafez K. Flaxseed oil significantly increases bleeding time in type 2 diabetes patients in Cape Breton, Nova Scotia, Canada. J Oleo Sci 2005;54:347-54.